Last reviewed · How we verify

NCT04659577

Attitudes of Professionals and the General Public in Israel Regarding ICBT

Completed NA Last updated 2 August 2022
What this trial tests

NA trial testing ICBT for panic and depression in Panic Disorder in 130 participants. Completed in 31 January 2022.

Timeline
1 November 2016
Primary endpoint
31 August 2021
31 January 2022

Quick facts

Lead sponsorHebrew University of Jerusalem
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment130
Start date1 November 2016
Primary completion31 August 2021
Estimated completion31 January 2022

Drugs / interventions tested

Conditions studied

Sponsor

Hebrew University of Jerusalem

Who can join

Adults 18 to 75, any sex, with Panic Disorder or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines uptake and attrition for internet based treatments for panic disorder and depression in Israel The primary benefits of this work will be a) in providing better understanding of ICBT for panic disorder and depression outcomes. Both panic and depression are heavy public health burdens, associated with a significant market potential for both therapeutic and diagnostic uses. b) In providing compatible scale to measure the working alliance during internet-based treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Panic Disorder

Currently open trials in the same condition.

Other Hebrew University of Jerusalem trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing